IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v9y2018i1d10.1038_s41467-018-04664-0.html
   My bibliography  Save this article

Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy

Author

Listed:
  • Ali Talebi

    (KU Leuven)

  • Jonas Dehairs

    (KU Leuven)

  • Florian Rambow

    (VIB Center for Cancer Biology
    KU Leuven)

  • Aljosja Rogiers

    (VIB Center for Cancer Biology
    KU Leuven)

  • David Nittner

    (VIB-KU Leuven Center for Cancer Biology
    KU Leuven)

  • Rita Derua

    (KU Leuven)

  • Frank Vanderhoydonc

    (KU Leuven)

  • Joao A. G. Duarte

    (KU Leuven
    VIB Center for Cancer Biology)

  • Francesca Bosisio

    (Department of Imaging and Pathology
    UZ Leuven)

  • Kathleen Eynde

    (Department of Imaging and Pathology
    UZ Leuven)

  • Kris Nys

    (KU Leuven)

  • Mónica Vara Pérez

    (KU Leuven)

  • Patrizia Agostinis

    (KU Leuven)

  • Etienne Waelkens

    (KU Leuven)

  • Joost Oord

    (Department of Imaging and Pathology
    UZ Leuven)

  • Sarah-Maria Fendt

    (KU Leuven
    VIB Center for Cancer Biology)

  • Jean-Christophe Marine

    (VIB Center for Cancer Biology
    KU Leuven)

  • Johannes V. Swinnen

    (KU Leuven)

Abstract

Whereas significant anti-tumor responses are observed in most BRAFV600E-mutant melanoma patients exposed to MAPK-targeting agents, resistance almost invariably develops. Here, we show that in therapy-responsive cells BRAF inhibition induces downregulation of the processing of Sterol Regulator Element Binding (SREBP-1) and thereby lipogenesis. Irrespective of the escape mechanism, therapy-resistant cells invariably restore this process to promote lipid saturation and protect melanoma from ROS-induced damage and lipid peroxidation. Importantly, pharmacological SREBP-1 inhibition sensitizes BRAFV600E-mutant therapy-resistant melanoma to BRAFV600E inhibitors both in vitro and in a pre-clinical PDX in vivo model. Together, these data indicate that targeting SREBP-1-induced lipogenesis may offer a new avenue to overcome acquisition of resistance to BRAF-targeted therapy. This work also provides evidence that targeting vulnerabilities downstream of oncogenic signaling offers new possibilities in overcoming resistance to targeted therapies.

Suggested Citation

  • Ali Talebi & Jonas Dehairs & Florian Rambow & Aljosja Rogiers & David Nittner & Rita Derua & Frank Vanderhoydonc & Joao A. G. Duarte & Francesca Bosisio & Kathleen Eynde & Kris Nys & Mónica Vara Pérez, 2018. "Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy," Nature Communications, Nature, vol. 9(1), pages 1-11, December.
    • Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04664-0
    DOI: 10.1038/s41467-018-04664-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-018-04664-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-018-04664-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jiaxin Liang & Deyang Yu & Chi Luo & Christopher Bennett & Mark Jedrychowski & Steve P. Gygi & Hans R. Widlund & Pere Puigserver, 2023. "Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    2. Tom Nyen & Mélanie Planque & Lilian Wagensveld & Joao A. G. Duarte & Esther A. Zaal & Ali Talebi & Matteo Rossi & Pierre-René Körner & Lara Rizzotto & Stijn Moens & Wout Wispelaere & Regina E. M. Baid, 2022. "Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers," Nature Communications, Nature, vol. 13(1), pages 1-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04664-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.